Clinical ink announced the appointment of Andrew Kraus as Chief Technology Officer who will lead the development of the company’s expanding technology portfolio to support clinical trials.
Newsroom
Clinical ink is delighted to announce its partnership with Teckro, a trailblazer in site user engagement and clinical trial technology solutions.
Clinical ink announces the publication of “Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study” in npj Parkinson’s Disease.
Clinical ink now offers continuous glucose monitoring (CGM) within its integrated digital biomarker solution.
Clinical ink announces its strategic partnership with Mural Health, a next-generation participant management platform.
Clinical ink, a global life science technology company, announces a strategic alliance with The Boston Clinical Research Institute (BCRI), an Academic Research Organization (ARO) based in Boston, Massachusetts. The alliance will combine BCRI’s leadership in clinical strategy, therapeutic area expertise, and academic collaboration with Clinical ink’s expertise in eSource technology.
Clinical ink, a global life science technology company, today announced that experienced healthcare industry veteran Dr. Jonathan Goldman MD has joined the company as Chief Executive Officer (CEO). Jonathan succeeds Ed Seguine who has led Clinical ink since nearly fourteen years ago.
Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease research to deploy remote technology that captures study participants’ symptoms at home and clinical sites in the United States and Europe.
